Chronicles in drug discovery.
Chronicles in Drug Discovery features special interest reports on advances in drug discovery. This month we highlight new options to prevent oral mucositis, a treatment-limiting adverse effect of chemotherapy. Studies are currently focusing on mechanism-based therapies to prevent or repair DNA damage to epithelial and submucosal cells and the cascade or events that follow to cause tissue damage or analgesics to ease the associated oral cavity pain. Therapeutic limitations also exist for the use of the highly effective antibiotic gentamicin, as it evokes acute renal failure. Mechanistic investigations have shed some light on potential targets: the kallikreins, peroxynitrite-related pathways, superoxide production and the accumulation of aminoglycosides. New antibiotic strategies for trachoma, the leading cause of preventable blindness, are also explored along with studies to aid the development of vaccine candidates. Finally, we discuss the utility of allosteric-potentiating ligands to modulate nicotinic acetylcholine receptors, mimicking the reward/addictive effects of nicotine, as potential strategies for smoking cessation.
Davies
Shelley L
SL
Prous Science, Barcelona, Spain.
Ferrer
Elisa
E
Moral
Maria Angels
MA
D015195:Drug Design; D006801:Humans; D017774:Long-Term Potentiation / Q000187:drug effects / Q000502:physiology; D008954:Models, Biological; D011978:Receptors, Nicotinic / Q000502:physiology; D016540:Smoking Cessation / Q000379:methods; D013280:Stomatitis / Q000188:drug therapy / Q000517:prevention & control; D013678:Technology, Pharmaceutical / Q000379:methods* / Q000639:trends; D014141:Trachoma / Q000188:drug therapy / Q000517:prevention & control
D011978:Receptors, Nicotinic